Hemoadsorption Using CytoSorb® in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis
Rao C, Preissing F, Thielmann M, Wendt D, Haidari Z, Kalisnik JM, Daake L, Traeger K.
J Cardiovascular Development and Disease 2023; 10(9):366
CytoSorb® Cost Analysis / Infective Endocarditis
The purpose of this analysis was to theoretically investigate the budget impact of a reduced intensive care stay in infective endocarditis (IE) patients treated with intraoperative CytoSorb® in the German Healthcare System.
Use of intraoperative hemoadsorption was found to result in 2,298€ saved per patient in the base- case scenario without therapy reimbursement. Savings increased to 3,804€ per patient where there was full device-specific reimbursement. Deterministic and probabilistic sensitivity analyses confirmed the robustness of savings, with a probability of savings of 99% and 100% in the base-case and full reimbursement scenarios, respectively.
In summary, intraoperative hemoadsorption in IE patients might have relevant economic benefits related to reduced ICU stay, resulting in improved resource use. Further evaluations in larger prospective cohorts are warranted.
Subscribe to our newsletter now!
Get access to the CytoSorbents Community Area. The current newsletter contains a direct link to the CytoSorbents Community Area.